By C. Landmon and C. Gallo, Ph.D., Axinn, Veltrop & Harkrider LLP
There is an upcoming regulatory “dead zone” that will potentially delay market entry of certain insulin products. A recent Senate bill has been proposed to address this regulatory anomaly. Industry players should monitor this bill and other efforts to address the insulin dead zone, given how critical this product is to so many people.
Evaluating how much a process step contributes to viral clearance is an essential part of process validation in order to be sure you are manufacturing safe drugs. Learn more about how HiScale 10/40, packed with MabSelect PrismA, is a reliable choice for the capture step in a virus clearance study.